Demographic and clinical characteristics
| Characteristic . | ADE (n = 151) . | ADEP (n = 151) . | Total (n = 302) . |
|---|---|---|---|
| Age, y | |||
| Median | 46 | 46 | 46 |
| Range | 19-59 | 17-59 | 17-59 |
| Sex | |||
| Male, n (%) | 83 (55) | 77 (51) | 160 (53) |
| Female, n (%) | 68 (45) | 74 (49) | 142 (47) |
| Race or ethnicity | |||
| White, n (%) | 123 (81) | 128 (85) | 251 (83) |
| Hispanic, n (%) | 9 (6) | 5 (3) | 14 (5) |
| African American, n (%) | 10 (7) | 9 (6) | 19 (6) |
| Oriental, n (%) | 3 (2) | 4 (3) | 7 (2) |
| Unknown/Other, n (%) | 6 (4) | 5 (3) | 11 (4) |
| ELN categories, n (%) | |||
| Favorable, n (%) | 22 (15) | 27 (18) | 49 (16) |
| Intermediate-I, n (%) | 62 (41) | 58 (38) | 120 (40) |
| Intermediate-II, n (%) | 17 (11) | 19 (13) | 36 (12) |
| Adverse, n (%) | 26 (17) | 18 (12) | 44 (15) |
| Unknown, n (%) | 24 (16) | 29 (19) | 53 (18) |
| FAB classification | |||
| M0, n (%) | 8 (5) | 7 (5) | 15 (5) |
| M1, n (%) | 31 (21) | 35 (23) | 66 (22) |
| M2, n (%) | 55 (36) | 51 (34) | 106 (35) |
| M4, n (%) | 27 (18) | 37 (25) | 64 (21) |
| M5, n (%) | 12 (8) | 11 (7) | 23 (8) |
| M6, n (%) | 10 (7) | 1 (<1) | 11 (4) |
| M7, n (%) | 1 (<1) | 4 (3) | 5 (2) |
| RAEB_T, n (%) | 3 (2) | 4 (3) | |
| Other (Ineligible), n (%) | 4 (3) | 1 (<1) | 5 (2) |
| LDH,U/L | |||
| Minimum | 98 | 91 | 91 |
| 25th percentile | 195 | 241 | 221 |
| Median | 336 | 450.5 | 389 |
| 75th percentile | 763 | 898 | 801 |
| Maximum | 2517 | 14 784 | 14 784 |
| WBC count, ×103/μL | |||
| Minimum | 0.7 | 0.2 | 0.2 |
| 25th percentile | 2.0 | 3.6 | 2.3 |
| Median | 4.5 | 16.0 | 10.4 |
| 75th percentile | 38.3 | 50.2 | 47.2 |
| Maximum | 345.0 | 302.3 | 345.0 |
| Characteristic . | ADE (n = 151) . | ADEP (n = 151) . | Total (n = 302) . |
|---|---|---|---|
| Age, y | |||
| Median | 46 | 46 | 46 |
| Range | 19-59 | 17-59 | 17-59 |
| Sex | |||
| Male, n (%) | 83 (55) | 77 (51) | 160 (53) |
| Female, n (%) | 68 (45) | 74 (49) | 142 (47) |
| Race or ethnicity | |||
| White, n (%) | 123 (81) | 128 (85) | 251 (83) |
| Hispanic, n (%) | 9 (6) | 5 (3) | 14 (5) |
| African American, n (%) | 10 (7) | 9 (6) | 19 (6) |
| Oriental, n (%) | 3 (2) | 4 (3) | 7 (2) |
| Unknown/Other, n (%) | 6 (4) | 5 (3) | 11 (4) |
| ELN categories, n (%) | |||
| Favorable, n (%) | 22 (15) | 27 (18) | 49 (16) |
| Intermediate-I, n (%) | 62 (41) | 58 (38) | 120 (40) |
| Intermediate-II, n (%) | 17 (11) | 19 (13) | 36 (12) |
| Adverse, n (%) | 26 (17) | 18 (12) | 44 (15) |
| Unknown, n (%) | 24 (16) | 29 (19) | 53 (18) |
| FAB classification | |||
| M0, n (%) | 8 (5) | 7 (5) | 15 (5) |
| M1, n (%) | 31 (21) | 35 (23) | 66 (22) |
| M2, n (%) | 55 (36) | 51 (34) | 106 (35) |
| M4, n (%) | 27 (18) | 37 (25) | 64 (21) |
| M5, n (%) | 12 (8) | 11 (7) | 23 (8) |
| M6, n (%) | 10 (7) | 1 (<1) | 11 (4) |
| M7, n (%) | 1 (<1) | 4 (3) | 5 (2) |
| RAEB_T, n (%) | 3 (2) | 4 (3) | |
| Other (Ineligible), n (%) | 4 (3) | 1 (<1) | 5 (2) |
| LDH,U/L | |||
| Minimum | 98 | 91 | 91 |
| 25th percentile | 195 | 241 | 221 |
| Median | 336 | 450.5 | 389 |
| 75th percentile | 763 | 898 | 801 |
| Maximum | 2517 | 14 784 | 14 784 |
| WBC count, ×103/μL | |||
| Minimum | 0.7 | 0.2 | 0.2 |
| 25th percentile | 2.0 | 3.6 | 2.3 |
| Median | 4.5 | 16.0 | 10.4 |
| 75th percentile | 38.3 | 50.2 | 47.2 |
| Maximum | 345.0 | 302.3 | 345.0 |
ADE indicates cytosine arabinoside, daunorubicin, and etoposide; ADEP, cytosine arabinoside, daunorubicin, etoposide, and PSC-833; ELN, European LeukemiaNet; FAB, French-American-British; RAEB_T, refractory anemia with excess blasts in transformation; LDH, lactate dehydrogenase; and WBC, white blood cell.